

Special Issue

Drug Discovery for Infectious Diseases

Message from the Guest Editors

Infectious diseases encompass a wide range of diseases caused by viruses, bacteria, fungi and parasites, all of which have serious consequences for human health. The rapid emergence of new viral and parasitic diseases, as well as the spread of antimicrobial resistance, is also putting drug research at a disadvantage, posing a challenge to the biomedical research field to develop new drugs and drug innovation strategies to keep pace with these new needs. Recent pandemics in particular highlight the need for novel antiviral drugs in several areas of human and animal health. This Special Issue welcomes reviews and papers describing host-entry and reproduction of the pathogen and pathomechanism of diseases at the molecular level, as well as those reporting on the discovery of new drug candidates that affect these processes. Innovative drug discovery strategies, including repositioning strategies from other pharmacological areas, drug combinations or multiple-targeting ligands, as well as new drug formulations for improved ADME, also represent suitable subjects of submitted papers.

Guest Editors

Dr. Péter Mátyus

1. E-Group ICT SOFTWARE, H-1027 Budapest, Hungary
2. Department of Organic Chemistry, Semmelweis University, H-1092 Budapest, Hungary

Dr. Ákos Jerzsele

Department of Pharmacology and Toxicology, University of Veterinary Medicine, 1078 Budapest, Hungary

Deadline for manuscript submissions

closed (30 April 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/112850

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).